Clinical Trial of Drugs For AMD

Age related macular degeneration can damageprofessor of Ophthalmology at Bascom Palmer
the eyes in an unwanted way. In particular, wetEye Institute named Dr. Philip J Rosenfeld has
AMD involves abnormal blood vessels growthconducted a research which showed that Avastin
behind the retina. Such kind of vessel formationcan improve eyesight for AMD patients
and growth leads to blood and fluid leakage. As asignificantly. According to this research, Avastin
result, the macula will be damaged and vision losscould show vision improvement within one week,
occurs. Wet form of AMD progresses morewhich was quite exiting compared to other
rapidly than dry AMD. Currently, there are sometreatments for wet AMD.
clinical trials of drugs that are potentially used toIn detail, a compounding pharmacy specializing in
fight against age related macular degeneration.sterile compounding will help transfer the Avastin
One of them is called anti-VEGF clinical trial whichfrom the manufacturer's vial into prefilled syringes.
is aimed to reduce the abnormal growth of bloodThe reason is that only a very small amount of
vessels associated with wet AMD. In the class ofAvastin is enough for retinal specialists to perform
drugs called anti-VEGF (Vascular Endothelialsuch kind of an injection. This injection can be
Growth Factor), Avastin is one that had receiveddone in an office setting.
FDA approval to treat tumors in 2004. CombinedAvastin is also being compared with another
with another chemotherapy drug, Avastin is usedtreatment for wet macular degeneration called
to treat metastatic colorectal cancer in practice.Lucentis. A clinical trial in this field is currently
Now, Avastin is under the clinical trial which seeksconducted by Emory Eye Center in Atlanta along
its effectiveness in treating wet form of agewith 47 other eye institutions.
related macular degeneration. An associated